Affymetrix and Cytox to co-develop Alzheimer’s Assay
LONDON: Affymetrix and Cytox have agreed to collaborate on developing and commercializing a blood-based genetic assay for research in diagnosis and prognosis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI).
